Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Portfolio Design Labs LLC

Portfolio Design Labs LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 302 shares of the biopharmaceutical company’s stock after buying an additional 26 shares during the quarter. Portfolio Design Labs LLC’s holdings in Regeneron Pharmaceuticals were worth $317,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. International Assets Investment Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after buying an additional 184,561 shares during the period. Swedbank AB acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at $129,257,000. Epoch Investment Partners Inc. acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at $99,667,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Regeneron Pharmaceuticals by 23.8% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock valued at $525,804,000 after buying an additional 96,266 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Barclays dropped their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Guggenheim upped their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Oppenheimer cut their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Finally, Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $1,099.55.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $743.35 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $736.01 and a 1-year high of $1,211.20. The firm has a market capitalization of $81.69 billion, a PE ratio of 18.40, a PEG ratio of 2.81 and a beta of 0.15. The business’s 50 day moving average is $961.76 and its 200-day moving average is $1,030.14. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.